[go: up one dir, main page]

AR045268A1 - Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento - Google Patents

Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento

Info

Publication number
AR045268A1
AR045268A1 ARP040102941A ARP040102941A AR045268A1 AR 045268 A1 AR045268 A1 AR 045268A1 AR P040102941 A ARP040102941 A AR P040102941A AR P040102941 A ARP040102941 A AR P040102941A AR 045268 A1 AR045268 A1 AR 045268A1
Authority
AR
Argentina
Prior art keywords
erbb2
overexpression
procedure
inhibitor
treatment
Prior art date
Application number
ARP040102941A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR045268A1 publication Critical patent/AR045268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento para tratar la sobreexpresión de erbB2 en un mamífero que necesite tratamiento, administrando al mamífero una cantidad terapéuticamente eficaz de un primer inhibidor del receptor de erbB2 tirosina quinasas receptoras y después, tras un intervalo de menos de 24 horas, administrar al mamífero de una a seis cantidades terapéuticamente eficaces del mismo inhibidor o de un inhibidor diferente del receptor de erbB2. Infusión diaria lenta del inhibidor de erbB2. La sobreexpresión del receptor de erbB2 puede dar como resultado un crecimiento celular anormal y conducir a un cáncer. Mediante los procedimientos del presente, se aumenta la eficacia y la seguridad de los inhibidores. Kits para facilitar el procedimiento de administración de la dosis del presente.
ARP040102941A 2003-08-18 2004-08-17 Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento AR045268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
AR045268A1 true AR045268A1 (es) 2005-10-19

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102941A AR045268A1 (es) 2003-08-18 2004-08-17 Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento

Country Status (18)

Country Link
US (1) US20050119288A1 (es)
EP (1) EP1658080A1 (es)
JP (1) JP2007502807A (es)
KR (2) KR20060037447A (es)
CN (1) CN1838959A (es)
AR (1) AR045268A1 (es)
AU (1) AU2004264726A1 (es)
BR (1) BRPI0413745A (es)
CA (1) CA2536140A1 (es)
CO (1) CO5670356A2 (es)
IL (1) IL173127A0 (es)
MX (1) MXPA06001989A (es)
NO (1) NO20061252L (es)
RU (1) RU2328287C2 (es)
SG (1) SG135193A1 (es)
TW (1) TW200522966A (es)
WO (1) WO2005016347A1 (es)
ZA (1) ZA200600517B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
ATE352550T1 (de) 2003-09-19 2007-02-15 Astrazeneca Ab Chinazolinderivate
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
KR20080027253A (ko) * 2005-06-16 2008-03-26 미리어드 제네틱스, 인크. 약제학적 조성물 및 이의 용도
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN102579467A (zh) * 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
DK1971601T3 (da) 2005-11-15 2010-02-08 Array Biopharma Inc N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
WO2007123661A2 (en) * 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
WO2007115286A2 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
JP2010523696A (ja) * 2007-04-10 2010-07-15 ミリアド ファーマシューティカルズ， インコーポレイテッド 脳腫瘍を治療する方法
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) * 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
MA33198B1 (fr) * 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2015115635A1 (ja) 2014-01-31 2015-08-06 凸版印刷株式会社 生体分子解析キット及び生体分子解析方法
AU2016343817B2 (en) * 2015-10-28 2021-05-27 Tva (Abc), Llc SSTR-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE205483T1 (de) * 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
BR0111548A (pt) * 2000-06-22 2003-05-06 Pfizer Prod Inc Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
CN1602195A (zh) * 2001-12-12 2005-03-30 辉瑞产品公司 用于治疗异常细胞生长的喹唑啉衍生物
HUP0402662A2 (hu) * 2001-12-12 2005-05-30 Pfizer Products Inc. Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk
WO2004046101A2 (en) * 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
MXPA05006335A (es) * 2002-12-18 2005-08-26 Pfizer Prod Inc Derivados biciclicos para el tratamiento del crecimiento celular anormal.

Also Published As

Publication number Publication date
KR20080014144A (ko) 2008-02-13
CO5670356A2 (es) 2006-08-31
BRPI0413745A (pt) 2006-10-24
CA2536140A1 (en) 2005-02-24
NO20061252L (no) 2006-05-16
IL173127A0 (en) 2006-06-11
ZA200600517B (en) 2007-02-28
US20050119288A1 (en) 2005-06-02
MXPA06001989A (es) 2006-05-17
CN1838959A (zh) 2006-09-27
EP1658080A1 (en) 2006-05-24
WO2005016347A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
RU2006102125A (ru) 2007-09-27
TW200522966A (en) 2005-07-16
JP2007502807A (ja) 2007-02-15
KR20060037447A (ko) 2006-05-03
SG135193A1 (en) 2007-09-28
AU2004264726A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AR045268A1 (es) Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
CR9984A (es) Método de inhibición de cinasa de tirosina cinasa 3 similar a fms
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
WO2018102687A3 (en) Combination therapy for treating cancer
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
RU2013125042A (ru) Способ предотвращения или лечения опухоли кожи
MX2024014317A (es) Tratamientos con nirogacestat
NO20051170L (no) Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
ZA202212095B (en) Il4i1 inhibitors and methods of use
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
MX2021001764A (es) Terapia de combinacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal